Our research results showed that regulating MFN2 affected key oxidative stress markers (ROS, MDA, 4-HNE, GSH) and pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in both in vivo and in vitro PD models. This evidence concerns the gene TNF and Parkinson disease.